Investigating Changes in Vital Signs in Neonates (Neo-vital)

December 15, 2023 updated by: University of Oxford

Neo-vital: Investigating Changes in Vital Signs in Neonates

1 in 7 babies require neonatal care. During their time in hospital their vital signs (such as heart rate, breathing rate and oxygen saturation) are continuously monitored as part of standard care. Many factors lead to changes in vital signs, for example, medical procedures such as blood tests can result in brief increases in heart rate. Medication can also alter vital signs, either as an intended effect or as a side effect. However, different infants will respond in different ways to both procedures and medication. Predicting how an individual infant may respond could lead to better individualised care for infants. For example, using an infant's baseline vital signs to predict whether they will experience cardiorespiratory side effects from a particular drug could mean that doctors could choose an alternative safer treatment plan. To develop these predictive models, it is essential to first better understand how infants' vital signs are affected by different procedures and drugs, and how these effects are impacted by other factors such as infection, other pathologies, interaction between drugs and age.

Despite their routine use in hospital neonatal units, detailed electronic records of vital signs are often not recorded. Often, only major events or average values are stated on clinical records. Subtle changes in vital signs are therefore missed, and more complex analysis that may reveal important predictive features within the data is not possible. In this study the investigators will electronically record infant vital signs across longer time periods and during a variety of clinically-necessary procedures and administration of drugs, to explore how these impact vital signs and are altered by factors such as age and pathology. These will be compared with control procedures, such as a nappy change, or when the infant is resting in their cot or receiving skin-to-skin care.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This single-centre prospective observational exploratory study will take place at the John Radcliffe Hospital, Oxford. Participants will be infants receiving inpatient care on the Newborn Care Unit.

Description

Inclusion Criteria:

Infants will be eligible to be included in the study if they are:

  • Born to, or expected to be born to, a mother aged 16 or over
  • Admitted to the Newborn Care Unit, John Radcliffe Hospital, or anticipated delivery of a baby who will require admittance to the Newborn Care Unit at birth
  • Mother given informed written consent

Exclusion Criteria:

Infants will be ineligible if the following exclusion criteria applies:

• Known chromosomal abnormality or life-threatening congenital abnormality

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in heart rate following drug administration
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
To characterise the change in heart rate in infants following drug administration in a wide range of commonly used drugs in neonatal care. Drugs will only be administered as part of clinical care, no drugs are administered for research purposes
1 day after drug administration, compared with baseline of 1 day before drug administration.
Change in oxygen saturation following drug administration
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
To characterise the change in oxygen saturation in infants following drug administration in a wide range of commonly used drugs in neonatal care. Drugs will only be administered as part of clinical care, no drugs are administered for research purposes
1 day after drug administration, compared with baseline of 1 day before drug administration.
Change in respiratory rate following drug administration
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
To characterise the change in heart rate in infants following drug administration in a wide range of commonly used drugs in neonatal care. Drugs will only be administered as part of clinical care, no drugs are administered for research purposes
1 day after drug administration, compared with baseline of 1 day before drug administration.
Change in heart rate following procedures
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
To characterise the change in heart rate in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.
1 day after procedure, compared with baseline of 1 day before procedure.
Change in oxygen saturation following procedures
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
To characterise the change in oxygen saturation in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.
1 day after procedure, compared with baseline of 1 day before procedure.
Change in respiratory rate following procedures
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
To characterise the change in respiratory rate in infants in relation to procedures, including (but not limited to) intubation and extubation, LISA (less invasive surfactant administration), blood transfusion and acute medically-required painful procedures.
1 day after procedure, compared with baseline of 1 day before procedure.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Models of drug response
Time Frame: 1 day after drug administration, compared with baseline of 1 day before drug administration.
Prediction of drug regimen requirements in individual infants from respiratory rate.
1 day after drug administration, compared with baseline of 1 day before drug administration.
Models of procedure response
Time Frame: 1 day after procedure, compared with baseline of 1 day before procedure.
Prediction of procedure outcome in individual infants (e.g. extubation success) from respiratory rate
1 day after procedure, compared with baseline of 1 day before procedure.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 20, 2023

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

August 9, 2023

First Submitted That Met QC Criteria

September 4, 2023

First Posted (Actual)

September 13, 2023

Study Record Updates

Last Update Posted (Actual)

December 21, 2023

Last Update Submitted That Met QC Criteria

December 15, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • PID16761

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infant

Subscribe